
Aytu BioPharma Secures Exclusive US Rights for Novel Antidepressant EXXUA
Aytu BioPharma, Inc. announced the signing of an exclusive agreement to commercialize EXXUA (gepirone) extended-release tablets (“EXXUA”) in the United States. Gepirone is a new chemical entity, and EXXUA is the first-in-class selective serotonin 5HT1a …